Retatrutide: What the Latest Phase 3 Data Tells Us -- and What Happens Next

For several years, retatrutide has carried one of the biggest reputations in obesity research. Now we finally have enough Phase 3 evidence to start separating the reputation from the data.

And the data is substantial.

Retatrutide, formerly known as LY3437943, is Eli Lilly's investigational once-weekly "triple agonist".

The molecule activates three hormone receptors:
- GLP-1
- GIP
- Glucagon

That distinguishes it from semaglutide (the active ingredient in Ozempic and Wegovy), which acts primarily through GLP-1, and Lilly's own tirzepatide (sold under the Mounjaro and Zepbound brands), which combines GLP-1 and GIP receptor agonism.

The additional glucagon component is one of the things that has made retatrutide scientifically interesting. GLP-1 and GIP signalling can influence appetite, insulin secretion, glucose regulation, and other metabolic processes. But glucagon signalling adds another metabolic pathway that can affect energy expenditure and lipid metabolism. The question has always been whether combining all three could produce meaningfully greater clinical effects without creating an unacceptable tradeoff in safety or tolerability.

Phase 2 provided an unusually strong hint, and Phase 3 has now provided much more convincing evidence.

THE EARLY SIGNS WERE ALREADY UNUSUAL

In the Phase 2 obesity study published in the New England Journal of Medicine in 2023, participants receiving the highest studied dose of retatrutide lost an average of 24.2% of their baseline body weight over 48 weeks. (The 8 mg groups averaged 22.8%.)

Even more strikingly, the weight-loss curves had not clearly flattened by the end of the study. At the time, those results placed retatrutide among the most effective pharmacological obesity treatments ever studied.

But Phase 2 involved only 338 participants, so the obvious question was whether those numbers would survive much larger trials. We now have an answer.

TRIUMPH-1: OBESITY WITHOUT DIABETES

TRIUMPH-1 enrolled 2,339 adults with obesity who did not have diabetes.

Participants were randomized to receive placebo or one of three target doses of retatrutide: 4 mg, 9 mg, or 12 mg once weekly. The peer-reviewed Phase 3 results were published in the New England Journal of Medicine on September 29, 2026.

Using the trial's treatment-regimen estimand, mean body-weight reductions at 80 weeks were:
- 4 mg: 17.6%
- 9 mg: 23.7%
- 12 mg: 25.0%
- Placebo: 3.9%

Lilly has also reported an efficacy estimand, which asks a somewhat different question by estimating outcomes had participants remained on treatment without certain interfering events. Under that analysis, average weight loss at 80 weeks reached 28.3% with 12 mg retatrutide.

Yes, it is tempting to reduce a clinical trial to one headline number, but different statistical estimands answer slightly different questions. The conservative takeaway does not require choosing the most flattering number, as retatrutide produced very large reductions in body weight under either analysis.

The trial also showed something that may eventually prove as important as the average: that a substantial proportion of participants reached weight-loss levels that historically would have been difficult to imagine with pharmacotherapy.

Under Lilly's reported efficacy analysis, 45.3% of participants receiving 12 mg lost at least 30% of their body weight. More than one quarter lost at least 35%. Among participants entering a prespecified extension with a BMI of at least 35, average weight loss with the highest-dose treatment reached approximately 30% by 104 weeks.

Those are extraordinary numbers for a pharmacological obesity trial. This can also be appropriately summed up in layman's terms as "whoa".

TRIUMPH-2: OBESITY WITH TYPE 2 DIABETES

Weight-loss medications generally produce smaller average reductions in people with type 2 diabetes than in comparable obesity trials without diabetes. TRIUMPH-2 therefore represented an important test.

The Phase 3 study randomized 1,152 participants with obesity or overweight and type 2 diabetes to 4 mg, 9 mg, or 12 mg retatrutide, or placebo.

At 80 weeks, using Lilly's efficacy estimand, average body-weight reductions were:
- 4 mg: 12.7%
- 9 mg: 19.1%
- 12 mg: 20.8%
- Placebo: 4.0%

The glycemic effects were also substantial, with average A1C falling by approximately 1.4 to 1.6 percentage points across the retatrutide groups from an average baseline A1C of 7.7%. At the 9 mg dose, 40% of participants reached an A1C below 5.7%, which falls below the diagnostic threshold for prediabetes. At the 12 mg dose, 59.5% of participants no longer met BMI criteria for obesity by the end of the study.

The trial also reported substantial changes in several cardiometabolic markers. At the highest dose, average triglycerides fell by approximately 39.5%, systolic blood pressure fell by approximately 10.8 mmHg, waist circumference decreased by approximately 16.9 cm, and high-sensitivity C-reactive protein decreased substantially.

Those measurements do not by themselves prove that retatrutide prevents cardiovascular events, but they do show that its effects extend beyond the number displayed on a scale.

WHAT ABOUT CARDIOVASCULAR OUTCOMES?

TRIUMPH-3 enrolled people with severe obesity and established cardiovascular disease. Participants lost approximately 21.6% of body weight with 9 mg retatrutide and 22.6% with 12 mg under the efficacy analysis. However, the cardiovascular event data requires considerably more restraint.

Major adverse cardiovascular events occurred less frequently than investigators had expected across both the retatrutide and placebo groups. For one composite cardiovascular endpoint, the hazard ratio numerically favoured retatrutide. For another, it did not. In both cases, the confidence intervals were broad and crossed 1.

That means TRIUMPH-3 does not establish that retatrutide reduces major cardiovascular events.

Lilly is conducting additional cardiovascular and renal outcome research. Until those studies mature, improvements in cardiovascular risk factors should not be confused with demonstrated cardiovascular-event reduction.

THE SAFETY STORY

Retatrutide's adverse-effect profile so far contains many things familiar from other incretin therapies, gastrointestinal effects remain the most common.

In TRIUMPH-2, diarrhea occurred in roughly 27% to 34% of retatrutide participants depending on dose, compared with about 13% receiving placebo. Nausea ranged from roughly 14% at 4 mg to 28% at 12 mg. Vomiting and constipation also became more common than with placebo. And TRIUMPH-1 showed a similar pattern.

One finding that deserves particular attention is dysesthesia -- abnormal sensations that may include tingling, burning, altered skin sensation, or related symptoms.

In TRIUMPH-1, Lilly reported dysesthesia in approximately 5.1% of participants receiving 4 mg, 12.3% receiving 9 mg, and 12.5% receiving 12 mg, compared with 0.9% receiving placebo. Most cases were described as mild to moderate and most resolved during treatment, but the dose-related pattern makes this a notable finding to follow.

Treatment discontinuation due to adverse events also increased at higher doses.

In TRIUMPH-1, discontinuation because of adverse events occurred in approximately 4.1% of participants receiving 4 mg, 6.9% receiving 9 mg, and 11.3% receiving 12 mg, compared with 4.9% receiving placebo.

That raises an interesting practical question. The highest dose produces the greatest average weight loss, but the optimal dose for an individual population may not simply be "as high as possible". The 4 mg arm still produced very substantial weight loss with fewer treatment discontinuations.

Future prescribing practices may therefore involve a more nuanced relationship between efficacy and tolerability than headline numbers suggest.

MORE THAN A WEIGHT-LOSS DRUG?

Lilly is studying retatrutide across an increasingly broad cardiometabolic program. That includes obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis associated with obesity, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease, and cardiovascular and renal outcomes.

TRIUMPH-1 already provides evidence that some benefits associated with major weight reduction extend into other conditions:
- Among participants with knee osteoarthritis, pain scores improved significantly compared with placebo.
- Among participants with obstructive sleep apnea, apnea-hypopnea events also declined substantially.

An important unanswered question is how much of those benefits comes directly from retatrutide's pharmacology and how much comes indirectly from substantial weight loss.

From the patient's perspective, that may not always matter. From a research perspective, it matters enormously.

WHAT HAPPENS NEXT?

This is where retatrutide's development story has changed considerably during 2026. Lilly now says it has the clinical data package needed to support global regulatory submissions for several obesity-related indications.

One regulatory wrinkle worth watching is Lilly's plan to submit retatrutide under a Biologics License Application, or BLA. That classification is controversial because FDA's current definition treats a "protein" as an amino-acid polymer of more than 40 amino acids, while retatrutide's principal peptide backbone contains 39. FDA previously concluded that retatrutide does not meet that protein definition, and a federal court upheld that part of the agency's reasoning, although the separate question of whether it could still qualify as "analogous" to a protein remains unresolved.

Lilly's BLA must be rejected. The impacts, if it is not, cannot be understated. Biologic status could make future competition more difficult and potentially delay lower-cost follow-on products compared with the conventional generic-drug pathway. We would prefer to see the regulatory classification follow the molecule itself rather than the commercial advantages of the BLA route. For a treatment that could eventually reach millions of people, anything that unnecessarily raises barriers to competition and affordability deserves scrutiny.

THE COMMERCIAL QUESTION MAY BE ALMOST AS INTERESTING AS THE SCIENTIFIC ONE

If approved, retatrutide would enter a market that Lilly itself has helped transform. Tirzepatide already produces weight loss that would have seemed extraordinary for a medication only a few years ago.

Retatrutide potentially pushes that boundary further.

But maximum efficacy is only one part of the competition:
- Cost will matter.
- Insurance coverage will matter.
- Supply will matter.
- Tolerability will matter.
- Convenience will matter.
- Long-term cardiovascular outcomes will matter.

And Lilly now has several of its own products competing for different portions of the same enormous cardiometabolic market. Retatrutide may therefore occupy a different role from simply "the drug that replaces tirzepatide".

Patients requiring very large reductions in body weight may eventually represent one obvious population. People doing well on established therapies may have little reason to change. Others may find lower retatrutide doses provide an attractive balance between effectiveness and tolerability.

We will not know how those patterns develop until regulators define the approved indication and dose structure and the drug begins accumulating real-world clinical experience.

WHAT THE EVIDENCE ACTUALLY SUPPORTS TODAY

As of October 2026, several conclusions are becoming increasingly difficult to dispute:
- Retatrutide produces substantial weight loss in randomized Phase 3 trials.
- Its efficacy extends to people with and without type 2 diabetes.
- It substantially improves glycemic control in type 2 diabetes.
- It produces meaningful changes in several cardiometabolic risk markers.
- It appears capable of producing weight reductions approaching those historically associated with bariatric surgery in a meaningful subset of participants.
- Its most common adverse effects are gastrointestinal, while dysesthesia has emerged as another notable treatment-associated effect worth following.

And Lilly now appears to have moved from proving that retatrutide works to assembling the regulatory and manufacturing package necessary to try to sell it.

What we cannot say yet is equally important:
- Retatrutide has not yet been approved by the FDA.
- Its final commercial label is unknown.
- A 2027 launch is possible, not guaranteed.
- Its very-long-term safety profile is not yet established.
- Its effect on major cardiovascular events has not yet been conclusively demonstrated.
- And clinical-trial results cannot tell us exactly how the medication will perform once used across millions of people in ordinary clinical practice.

The retatrutide story has therefore entered an interesting phase, because the question is no longer whether the extraordinary Phase 2 results were simply a small-study curiosity; Phase 3 has largely answered that.

The next questions are regulatory, commercial, and long-term:
- What does the FDA approve?
- At which doses?
- For which indications?
- How does Lilly position it alongside tirzepatide and its other metabolic therapies?
- And what happens when controlled trial evidence finally meets large-scale real-world use?

We should begin getting those answers in 2027.


Sources and further reading:

New England Journal of Medicine. 2023;389:514-526.
https://doi.org/10.1056/NEJMoa2301972

Jastreboff AM, et al. "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." New England Journal of Medicine. Published September 29, 2026.
https://doi.org/10.1056/NEJMoa2604169

Bellido V, et al. "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial." The Lancet. Published September 29, 2026.
https://doi.org/10.1016/S0140-6736(26)01861-1

Bajaj HS, et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1)." The Lancet. 2026.
https://doi.org/10.1016/S0140-6736(26)00967-0

Eli Lilly and Company. "Lilly's triple agonist retatrutide successful in two additional Phase 3 trials." 2026.
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

Eli Lilly and Company. Retatrutide clinical development information.
https://www.lilly.com/news/stories/what-is-retatrutide

ClinicalTrials.gov. Retatrutide studies and clinical development program.
https://clinicaltrials.gov/search?term=retatrutide

U.S. Food and Drug Administration. "The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective."
https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

\ Get the latest news /